Fruzaqla (fruquintinib) — Medica
Colon cancer
Initial criteria
- age ≥ 18 years
- advanced or metastatic disease
- Patient meets ONE of the following (i or ii): i) proficient mismatch repair/microsatellite-stable (pMMR/MSS) disease; OR ii) ineligible for or progressed on checkpoint inhibitor therapy AND meets ONE of the following (a or b): a) deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) disease; OR b) polymerase epsilon/delta (POLE/POLD1) mutation positive
- Previously treated with ALL of the following: i) Fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; AND ii) An anti-vascular endothelial growth factor (VEGF) agent; AND iii) If RAS wild-type (KRAS and NRAS mutation negative), patient meets ONE of the following (a or b): a) Anti-epidermal growth factor receptor (EGFR) therapy is NOT medically appropriate; OR b) Has received an anti-EGFR therapy
Approval duration
1 year